Lung Cancer, Lung Neoplasms
Conditions
Brief summary
This is a phase 2, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/positron emission tomography imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to assess the safety and tolerability of single intravenous doses of OTL38.
Detailed description
This is a phase 2, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/positron emission tomography (PET) imaging based on standard of care. Two to three hours prior to surgery, patients will be infused with OTL38. After the patient is intubated and surgical site incised, the surgeon will locate and document all nodules identifiable by white light, manual palpation, and Near-Infrared Imaging (NIR). This will be documented and recorded. Surgery will be completed per surgeon's standard of care, afterwards the area will be reviewed under standard and infrared light. All samples will be sent for pathology and immunohistochemistry (IHC) evaluation.
Interventions
Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Near infrared camera imaging system
PROCEDUREEndoscopic or Thoracic Surgery
Endoscopic or Thoracic Surgery
Sponsors
Medelis Inc.
On Target Laboratories, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Male and Female patients 18 years of age and older 2. Confirmed diagnosis of adenocarcinoma lung cancer OR, 3. Have a primary diagnosis, or at high clinical suspicion, of lung nodule(s) warranting surgery based on CT and/or PET imaging 4. Who are scheduled to undergo endoscopic or thoracic surgery surgery 5. A negative serum pregnancy test at Screening followed by a negative urine pregnancy test on the day of surgery or day of admission for female patients of childbearing potential 6. Female patients of childbearing potential or less than 2 years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until 30 days after study completion 7. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments
Exclusion criteria
1. Previous exposure to OTL38 2. Known Folate Receptor-negative lung nodules 3. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the patient 4. History of anaphylactic reactions or severe allergies 5. History of allergy to any of the components of OTL38, including folic acid 6. Pregnancy, or positive pregnancy test 7. Clinically significant abnormalities on electrocardiogram (ECG) at screening. 8. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule 9. Impaired renal function defined as epidermal growth factor receptor (eGFR) \< 50 mL/min/1.73m2 10. Impaired liver function defined as values \> 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin. 11. Received an investigational agent in another investigational drug or vaccine trial within 30 days prior to surgery 12. Known sensitivity to fluorescent light
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity or True Positive Rate (TPR) | 1 day | Sensitivity or True Positive Rate (TPR) for OTL38 in combination with fluorescent light, defined as the proportion of fluorescent light positive tissue samples (nodule, synchronous lesion, and margin but excluding lymph nodes) that are histologically confirmed to be FR+ and lung cancer by central pathology relative to the total number of tissue samples confirmed to be FR+ and lung cancer by central pathology. Sensitivity = (True Positive)/(True Positive +False Negative) |
| False Positive Rate (FPR) | 1 day | False positive rate (FPR) for OTL38 in combination with fluorescent light, for the purpose of this protocol, will be calculated as 1 - the Positive Predictive Value (PPV) and is defined as the proportion of fluorescent light positive tissue samples removed (nodule, synchronous lesion, and margin but excluding lymph nodes) that are histologically confirmed to be non-cancerous, or if cancerous, not FR+ and lung cancer, by central pathology relative to the total number of tissue samples removed with fluorescent light imaging. False Positive Rate = (False Positives) / (True Positives + False Positives) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Positive Margin Identification | 1 day | Number of patients where at least one positive margin (fluorescent cancerous cells within 5 mm of the staple line) is identified with only OTL-38 and NIR |
| Synchronous Lesion Identification | 1 day | Number of patients where at least one synchronous lesions is identified only with OTL-38 and NIR |
| Pulmonary Nodule Identification | 1 day | Number of pulmonary nodules identified with OTL-38 and Near Infrared Imaging (NIR) that could not otherwise be identified by white light and palpation. |
| Proportion of Patients With at Least 1 Clinically Significant Event (CSE) | 1 day | Proportion of patients with at least 1 Clinically Significant Event (CSE as a result of utilizing OLT-38 and Near Infrared Imaging |
Countries
Netherlands, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Patients Receiving OTL38 All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
OTL38 for Injection: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Near infrared camera imaging system: Near infrared camera imaging system
Endoscopic or Thoracic Surgery: Endoscopic or Thoracic Surgery | 100 |
| Total | 100 |
Baseline characteristics
| Characteristic | Patients Receiving OTL38 |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 72 Participants |
| Age, Categorical Between 18 and 65 years | 28 Participants |
| Age, Continuous | 67.4 years STANDARD_DEVIATION 9.35 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 98 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 7 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 86 Participants |
| Region of Enrollment Netherlands | 10 Participants |
| Region of Enrollment United States | 90 Participants |
| Sex: Female, Male Female | 68 Participants |
| Sex: Female, Male Male | 32 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 100 |
| other Total, other adverse events | 94 / 100 |
| serious Total, serious adverse events | 14 / 100 |
Outcome results
Primary
False Positive Rate (FPR)
False positive rate (FPR) for OTL38 in combination with fluorescent light, for the purpose of this protocol, will be calculated as 1 - the Positive Predictive Value (PPV) and is defined as the proportion of fluorescent light positive tissue samples removed (nodule, synchronous lesion, and margin but excluding lymph nodes) that are histologically confirmed to be non-cancerous, or if cancerous, not FR+ and lung cancer, by central pathology relative to the total number of tissue samples removed with fluorescent light imaging. False Positive Rate = (False Positives) / (True Positives + False Positives)
Time frame: 1 day
Population: The FAS for the analysis of the two co-primary endpoints, sensitivity and FPR, included patients exposed to OTL38 who:~* Were evaluated under both normal light and fluorescent light imaging, and~* Had central pathology and histology confirmation (positive for FR+ Lung Cancer) for at least one tissue sample detected under normal light or fluorescent light imaging
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Patients Receiving OTL38 | False Positive Rate (FPR) | 0.138 proportion of lesions |
Primary
Sensitivity or True Positive Rate (TPR)
Sensitivity or True Positive Rate (TPR) for OTL38 in combination with fluorescent light, defined as the proportion of fluorescent light positive tissue samples (nodule, synchronous lesion, and margin but excluding lymph nodes) that are histologically confirmed to be FR+ and lung cancer by central pathology relative to the total number of tissue samples confirmed to be FR+ and lung cancer by central pathology. Sensitivity = (True Positive)/(True Positive +False Negative)
Time frame: 1 day
Population: The FAS for the analysis of the two co-primary endpoints, sensitivity and FPR, included patients exposed to OTL38 who:~* Were evaluated under both normal light and fluorescent light imaging, and~* Had central pathology and histology confirmation (positive for FR+ Lung Cancer) for at least one tissue sample detected under normal light or fluorescent light imaging
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Patients Receiving OTL38 | Sensitivity or True Positive Rate (TPR) | 0.854 proportion of lesions |
Secondary
Positive Margin Identification
Number of patients where at least one positive margin (fluorescent cancerous cells within 5 mm of the staple line) is identified with only OTL-38 and NIR
Time frame: 1 day
Population: The FAS for the analysis of the two co-primary endpoints, sensitivity and FPR, included patients exposed to OTL38 who:~* Were evaluated under both normal light and fluorescent light imaging, and~* Had central pathology and histology confirmation (positive for FR+ Lung Cancer) for at least one tissue sample detected under normal light or fluorescent light imaging
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients Receiving OTL38 | Positive Margin Identification | 8 Participants |
Secondary
Proportion of Patients With at Least 1 Clinically Significant Event (CSE)
Proportion of patients with at least 1 Clinically Significant Event (CSE as a result of utilizing OLT-38 and Near Infrared Imaging
Time frame: 1 day
Population: The FAS for the analysis of the two co-primary endpoints, sensitivity and FPR, included patients exposed to OTL38 who:~* Were evaluated under both normal light and fluorescent light imaging, and~* Had central pathology and histology confirmation (positive for FR+ Lung Cancer) for at least one tissue sample detected under normal light or fluorescent light imaging
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Patients Receiving OTL38 | Proportion of Patients With at Least 1 Clinically Significant Event (CSE) | 0.293 proportion of participants |
Secondary
Pulmonary Nodule Identification
Number of pulmonary nodules identified with OTL-38 and Near Infrared Imaging (NIR) that could not otherwise be identified by white light and palpation.
Time frame: 1 day
Population: The FAS for the analysis of the two co-primary endpoints, sensitivity and FPR, included patients exposed to OTL38 who:~* Were evaluated under both normal light and fluorescent light imaging, and~* Had central pathology and histology confirmation (positive for FR+ Lung Cancer) for at least one tissue sample detected under normal light or fluorescent light imaging
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Patients Receiving OTL38 | Pulmonary Nodule Identification | 10 number of pulmonary nodules |
Secondary
Synchronous Lesion Identification
Number of patients where at least one synchronous lesions is identified only with OTL-38 and NIR
Time frame: 1 day
Population: The FAS for the analysis of the two co-primary endpoints, sensitivity and FPR, included patients exposed to OTL38 who:~* Were evaluated under both normal light and fluorescent light imaging, and~* Had central pathology and histology confirmation (positive for FR+ Lung Cancer) for at least one tissue sample detected under normal light or fluorescent light imaging
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Patients Receiving OTL38 | Synchronous Lesion Identification | 7 Participants |